Wishing you all the joys of the season! 
North America Cell and Gene Therapy Manufacturing Services Market Forecast to 2030
North America Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 – Regional Analysis – by Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral and Non-Viral Vector)], Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing Drives North America Cell and Gene Therapy Manufacturing Services Market
Cell and gene therapy manufacturing is a complex process, which makes the proper execution and overseeing of the operation crucial. Cell and gene therapy manufacturers have a limited number of qualified personnel who know biological and process engineering. Moreover, for experienced teams, managing the attempts to reach the first clinical trial using a manual, and open manufacturing method and then building a more commercially suitable process can be tricky. Therefore, these enterprises choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization process. CDMOs provide product development, manufacturing, clinical trial support, and commercialization services to cell and gene therapy companies on a contract basis. Partnering with a CDMO enables scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies for cell and gene therapy manufacturers. In April 2022, ThermoGenesis established a CDMO facility in California, US to provide CDMO services to cell and gene therapy manufacturers, using its expertise in T-cell receptor (TCR), chimeric antigen receptor-T cell (CAR-T cell), tumor-infiltrating leukocyte (TIL), iPSC, natural killer cell (NK), and mesenchymal stem cell (MSC) manufacturing. Outsourcing cell and gene therapy manufacturing to CDMOs proves cost-effective for manufacturers. Thus, the increasing preference for outsourcing growing cell and gene therapy manufacturing to CDMOs fuels the North America cell and gene therapy manufacturing services market growth.
North America Cell and Gene Therapy Manufacturing Services Market Overview
Cell and gene therapies (CGTs) treat patients suffering from serious and rare diseases with unaddressed therapeutic needs. Manufacturing CGTs is a highly complex process, with the insufficiency of infrastructure and expertise being a major limiting factor. Logistical challenges associated with intermediates and the final product also limit the CGT manufacturing capacity of companies. The CGT manufacturing process involves the extraction of autologous cells through “apheresis,” dispatching them to specialized labs, and sending them back to clinics for administration into patients, all of which must be performed with strict quality control. The US Food and Drug Administration (USFDA) has approved only 7 CGT drugs, with the pipeline of new products reaching ~1,200 experimental therapies. Half of these are in Phase 2 clinical trials, with estimates of annual sales growth accounting for 15% for cell therapies and ~30% for gene therapies, as per the estimates of the Chemical & Engineering News report 2022. On March 31, 2022, CELL Technologies Inc. announced the submission of the clinical data of its stem cell program in pain and arthritis for approval by Health Canada to help patients access evidence-based and regulatory-approved stem cell procedures across Canada. Thus, the abovementioned factors are expected to promote the cell and gene therapy manufacturing services market growth during the forecast period. Thus, the abovementioned factors are responsible for the growth of the North America cell and gene therapy manufacturing services market.
North America Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)
North America Cell and Gene Therapy Manufacturing Services Market Segmentation
The North America cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.
Based on type, the North America cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the North America cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.
Based on indication, the North America cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the North America cell and gene therapy manufacturing services market.
Based on application, the North America cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the North America cell and gene therapy manufacturing services market.
Based on end user, the North America cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the North America cell and gene therapy manufacturing services market.
Based on country, the North America cell and gene therapy manufacturing services market is segmented into the US, Canada, Mexico. In 2022, the US registered the largest share in the North America cell and gene therapy manufacturing services market.
Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, National Resilience Inc, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the North America cell and gene therapy manufacturing services market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America cell and gene therapy manufacturing services market was valued at US$ 4,153.27 million in 2022 and is expected to reach US$ 14,711.72 million by 2030, registering a CAGR of 17.1% from 2022 to 2030. Increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing are among the critical factors attributed to the North America cell and gene therapy manufacturing services market expansion.
The advancements in biotechnology have led to the adoption of personalized treatments for a wide range of indications. Stem cell therapies are being used to treat chronic diseases, such as cancer, neurological disorders, and genetic disorders. Further, the advantages of cell therapy, such as targeted treatment, faster and efficient recovery, and reduced side effects, promote the adoption of various products. Globally, cell therapies are widely adopted owing to the availability of Food and Drug Administration (FDA) approved products. Following is the list of cell and gene therapy products approved by FDA in recent years:
• In April 2020, the FDA awarded regenerative medicine advanced therapy designation to Novartis’ Kymriah to treat refractory (r/r) follicular lymphoma (FL) in adults.
• In July 2020, the FDA approved a CAR T-cell therapy brexucabtagene autoleucel (Tecartus) for patients with mantle cell lymphoma. It is the first FDA-approved CAR T-cell therapy for mantle cell lymphoma, and it was approved under the Accelerated Approval pathway. Tecartus also received Orphan Drug designation, which encourages the development of drugs for rare diseases. The other approved CAR-T cell therapies for cancer are Kymriah for acute lymphoblastic leukemia and Yescarta for diffuse large B-cell lymphoma.
• In 2022, ADSTILADRIN, an adenovirus manufactured by Ferring Pharmaceuticals A/S, was approved by FDA. This recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium to treat patients with certain types of bladder cancer.
• In 2022, CARVYKTI, manufactured by Janssen Biotech, Inc.—an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells for treatment of certain kinds of relapsed or refractory multiple myeloma—was also approved by FDA.
• In 2022, FDA approved HEMGENIX, manufactured by CSL Behring LLC, which is a recombinant AAV5 delivers F9 to treat patients with certain kinds of Hemophilia B.
• In 2022, FDA approved VYJUVEK, manufactured by Krystal Biotech, Inc., for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Therefore, the increasing approval of cell and gene therapies is fueling the growth of North America cell and gene therapy manufacturing services market.
On the contrary, high cost of cell and gene therapy manufacturing hurdles the growth of North America cell and gene therapy manufacturing services market.
Based on type, the North America cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 67.7% share of North America cell and gene therapy manufacturing services market in 2022, amassing US$ 2,810.13 million. It is projected to garner US$ 10,084.57 million by 2030 to expand at 17.3% CAGR during 2022-2030. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.
Based on indication, the North America cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. The cancer segment held 55.9% share of North America cell and gene therapy manufacturing services market in 2022, amassing US$ 2,320.41 million. It is projected to garner US$ 8,766.41 million by 2030 to expand at 18.1% CAGR during 2022-2030.
Based on application, the North America cell and gene therapy manufacturing services market is bifurcated into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held 62.8% share of North America cell and gene therapy manufacturing services market in 2022, amassing US$ 2,609.36 million. It is projected to garner US$ 9,734.30 million by 2030 to expand at 17.9% CAGR during 2022-2030.
Based on end user, the North America cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). The pharmaceutical and biotechnology companies segment held 79.0% share of North America cell and gene therapy manufacturing services market in 2022, amassing US$ 3,280.09 million. It is projected to garner US$ 11,705.28 million by 2030 to expand at 17.2% CAGR during 2022-2030.
Based on country, the North America cell and gene therapy manufacturing services market is segmented into the US, Canada, Mexico. Our regional analysis states that the US captured 80.3% share of North America cell and gene therapy manufacturing services market in 2022. It was assessed at US$ 3,334.61 million in 2022 and is likely to hit US$ 11,822.40 million by 2030, exhibiting a CAGR of 17.1% during 2022-2030.
Key players operating in the North America cell and gene therapy manufacturing services market are Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, National Resilience Inc, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co LtdĀ, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cell and gene therapy manufacturing services market.
o Highlights key in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Increase in Number of Approval of Cell and Gene Therapies
4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
4.2 Market Restraints
4.2.1 High Cost of Cell and Gene Therapy Manufacturing
4.3 Market Opportunities
4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
4.5 Impact Analysis:
5. Cell and Gene Therapy Manufacturing Services Market – North America Market Analysis
5.1 North America Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
6. North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Cell Therapy
6.3.1 Overview
6.3.2 Cell Therapy: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Autologous
6.3.2.1.1 Overview
6.3.2.1.2 Autologous: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Allogenic
6.3.2.2.1 Overview
6.3.2.2.2 Allogenic: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Gene Therapy
6.4.1 Overview
6.4.2 Gene Therapy: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Viral Vector
6.4.2.1.1 Overview
6.4.2.1.2 Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.2 Non-Viral Vector
6.4.2.2.1 Overview
6.4.2.2.2 Non-Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 – by Indication
7.1 Overview
7.2 North America Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Orthopedics
7.4.1 Overview
7.4.2 Orthopedics: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
8.4 Clinical Manufacturing
8.4.1 Overview
8.4.2 Clinical Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Commercial Manufacturing
8.5.1 Overview
8.5.2 Commercial Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
9.4 Pharmaceutical and Biotechnology Companies
9.4.1 Overview
9.4.2 Pharmaceutical & Biotechnology Companies: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Contract Research Organizations (CROs)
9.5.1 Overview
9.5.2 Contract Research Organizations (CROs): North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1 North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
10.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.1.1.1 US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.1.2 US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.1.3 US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.1.4 US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.2.1.1 Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.2.1.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.2.2 Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.2.3 Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.4 Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 Mexico: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.3.1.1 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.3.1.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.3.2 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.3.3 Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.4 Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
11. North America Cell and Gene Therapy Manufacturing Services Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Thermo Fisher Scientific Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck KGaA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Lonza Group AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Catalent Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Takara Bio Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Nikon Corp
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 FUJIFILM Holdings Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 National Resilience Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
12.11 Oxford BioMedica Plc
12.11.1 Key Facts
12.11.2 Business Description
12.11.3 Products and Services
12.11.4 Financial Overview
12.11.5 SWOT Analysis
12.11.6 Key Developments
LIST OF TABLES
Table 1. North America Cell and Gene Therapy Manufacturing Services Market Segmentation
Table 2. US: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. US: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. US: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. US: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. US: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. US: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. Canada: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. Canada: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. Canada: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 12. Canada: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. Canada: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. Mexico: Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. Mexico: Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Recent Organic Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
Table 21. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Manufacturing Services Market
LIST OF FIGURES
Figure 1. North America Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
Figure 2. North America Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Cell Therapy: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Autologous: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Allogenic: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Gene Therapy: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Non-Viral Vector: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. North America Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 13. Cancer: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Orthopedics: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 17. Clinical Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Commercial Manufacturing: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 20. Pharmaceutical & Biotechnology Companies: North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Contract Research Organizations (CROs): North America Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. North America: Cell and Gene Therapy Manufacturing Services Market, by Key Region – Revenue (2022) (US$ Million)
Figure 23. North America: Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
Figure 24. US: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Canada: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Mexico: Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Growth Strategies in Cell and Gene Therapy Manufacturing Services Market
The List of Companies – North America Cell and Gene Therapy Manufacturing Services Market
1. Catalent Inc
2. Charles River Laboratories International Inc
3. FUJIFILM Holdings Corp
4. Lonza Group AG
5. Merck KgaA
6. National Resilience Inc
7. Nikon Corp
8. Oxford BioMedica Plc
9. Takara Bio Inc
10. Thermo Fisher Scientific Inc
11. WuXi AppTec Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.